HIGHLY PATHOGENIC AVIAN INFLUENZA

VACCINATION RULES IN THE EU

WOAH 90TH GENERAL SESSION

Paris, 22 May 2023
Outline of the presentation

- HPAI situation in the EU
- Animal Health Law – EU legislative framework for animal health
- Rules on vaccination
- Vaccination and scientific trials in certain EU Member States
HPAI in Europe in birds in 2020 - 2023

Oct 2020 – Sept 2021

Virus spread with wild birds in all parts of Europe

Recurrent clusters in poultry in certain areas with high density of certain poultry production
Number of HPAI detections 2020-2023

Distribution of total number of HPAI virus detections reported in Europe by week of suspicion and
- affected poultry categories (up)
- affected wild bird categories (down)

Poultry:
- High peaks of outbreaks in the past
- Currently reduced number of outbreaks
- Main affected species: ducks

Wild birds:
- Seasonality in the past, related with autumn and spring migration
- Main affected species: waterfowl
- Worrying trend since spring 2022:
  - Persistence of HPAI virus in wild birds during summer
  - New species highly affected playing a role in spreading, i.e. seabirds breeding in colonies

Source EFSA
Summary of HPAI epidemic seasons in figures

2022-2023 the most severe HPAI epidemic season ever experienced by EU with the highest number of outbreaks in wild birds and poultry

Current epidemic season:
- still high number of outbreaks in wild birds
- less outbreaks in poultry (improved biosecurity and preventive measures e.g. reduced density in high risk areas)
ANIMAL HEALTH LAW
ANIMAL HEALTH LAW
Regulation (EU) 2016/429

Part I
- Delegated Regulation (DR) 2018/1620
  - List of diseases

Part II
- Implementing Regulation (IR) 2018/1882
  - Categories of diseases
- Delegated Regulation (DR) 2020/689
  - Surveillance, eradication & disease free
- Delegated Regulation (DR) 2020/687
  - Prevention & control of Cat A, B & C diseases
- Implementing Regulation (IR) 2020/690
  - Listing Union Surveillance Programmes & Compartments
- Delegated Regulation (DR) 2021/620
  - Listing of existing disease free and eradication programmes (MIs & zones)

Part III
- Delegated Regulation (DR) 2019/2035
  - Registration & approval of establishments & traceability (TPAO)
- Delegated Regulation (DR) 2020/688
  - Registration & identification of horses
- Delegated Regulation (DR) 2020/686
  - Approvals of establishments & intra EU movements (T)

Part IV
- Delegated Regulation (DR) 2020/685
  - Aquaculture animal establishments & transporters of aquatic animals (A)
- Delegated Regulation (DR) 2020/691
  - Aquaculture animal establishments & transporters of aquatic animals (A)
- Delegated Regulation (DR) 2020/684
  - Registration & traceability (T except horses)

Part V
- Delegated Regulation (DR) 2020/687
  - Approvals of establishments & intra EU movements (G)
- Delegated Regulation (DR) 2020/692
  - Entry into the EU (T/ A/ G/ TPAO/ APAO)
- Implementing Decision (ID) 2021/260
  - Recognition of existing national measures (A)
- Implementing Regulation (IR) 2020/990
  - Movement of aquatic animal (A) and products (APAO)
- Implementing Regulation (IR) 2020/999
  - Movement of aquatic animal (A) and products (APAO)
- Implementing Regulation (IR) 2020/690
  - Movement of aquatic animal (A) and products (APAO)
- Implementing Regulation (IR) 2020/689
  - Registration & traceability (T)
- Implementing Regulation (IR) 2020/688
  - Registration & traceability (T)
- Implementing Regulation (IR) 2020/686
  - Registration & traceability (G)
AHL: Rules for the use of VMPs for disease prevention and control

Article 46(1)

Provides for the possibility for the Member States to take measures concerning the use of (ALL) veterinary medicinal products to ensure the most efficient prevention or control of (ALL) listed diseases. These measures may cover prohibitions, restrictions and compulsory use of veterinary medicinal products and must be previously assessed as appropriate and necessary.

Article 47(1) (empowerment)

Empowers the Commission to adopt delegated acts concerning:

- prohibitions and restrictions on the use of veterinary medicinal products;
- specific conditions for the use of veterinary medicinal products for a specific listed disease;
- risk-mitigation measures to prevent the spread of listed diseases through animals treated with the veterinary medicinal products or products from such animals;
- surveillance for specific listed diseases following the use of vaccines and other veterinary medicinal products.

Article 69 - Emergency vaccination:

To take into account Art. 46(1) and delegated acts adopted pursuant to Art. 47
Delegated Regulation (EU) 2023/361

on the use of veterinary medicinal products for disease prevention and control
Rules on the use of **certain VMPs** for prevention and control of certain listed diseases - Terrestrial and Aquatic animals

Circumstances under which **vaccines for category A diseases** can be used

Which **VMPs cannot be used** for category A and B diseases (including some vaccines, i.e. Rinderpest and Mycobacterium tuberculosis complex)

Rules on the use of **vaccines** for prevention and control of category A diseases – Terrestrial animals (partially Aquatic)

- Preconditions
- Strategies
- General rules
- Risk-mitigation measures (movement restrictions)

**Disease-specific conditions**

- Implementation + post vaccination surveillance
- Measures (movement prohibitions for animals and products) in the vaccination zone
- Recovery of the previous animal health status

Approach
Vaccination strategies for HPAI

- Vaccination
  - Emergency
  - Preventive
- Suppressive
  - Protective

Stamping out: compulsory measure in all establishments where HPAI is detected
Specific rules for vaccination against HPAI

Vaccines
- that do not contain live AI virus (attenuated or not)

Reinforced surveillance
- clinical and laboratory (official activity)
- to assess effectiveness (emergency protective vaccination)
- to early detect infection with HPAI virus

Risk mitigation measures
- General prohibition for movements of vaccinated poultry and their products
- Derogations to move, under conditions

Traceability/Certificates
- Emergency vaccination: certificates for movements from vaccination zone within MS and to other MS
- Preventive vaccination: certificates for poultry and hatching eggs when moved to other MS
Decision Making - Implementation process for the use of vaccines against HPAI

**Member State**
- **Assessment of the situation** based on specific criteria (*Annex II of DR (EU) 2023/361*)
- **DECISION TO VACCINATE** (*strategy selection etc.*)
- Preparation of official vaccination plan (*in accordance with information required in Annex III of DR (EU) 2023/361*)

**Member State**
- Preliminary information sent *to the other MS and the COM* (at least 2 days before start of vaccination)
- **INITIATION OF VACCINATION**
- Official vaccination plan sent *to the other MS and the COM* (at the latest 2 weeks after start of vaccination)

**COM**
- Review of the national measures in the official vaccination plan. May act with additional measures in accordance with Article 71 of Regulation (EU) 2016/429

**Member State**
- **Disease-specific surveillance – Risk mitigation measures** (*Annex XIII of DR (EU) 2023/361*)
- **Regular reports** sent *to the other MS and the COM* (content / intervals according to the vaccination strategy – Annexes V and VI of DR (EU) 2023/361)
EFSA mandate for HPAI vaccination

Mandate formally sent to EFSA

Mandate formally accepted by EFSA

14 July 2022

Sept. 2022

July 2023

March 2024

1st delivery for questions on:
- vaccines
- vaccination strategies

2nd delivery for questions on:
- surveillance
- risk-mitigation measures

14 July 2022

Sept. 2022

July 2023

March 2024
VACCINATION SCIENTIFIC TRIALS

in certain EU Member States
Vaccination against HPAI in the Czech Republic

CZECH REPUBLIC

vaccination in the genetic reserve for national breed of geese

21.05.2023 – 25.05.2023, Paris
The occurrence of HPAI in the establishment with Czech geese in 2021

- The establishment (2 farms) is registered as a **poultry genetic resource** at the Ministry of Agriculture of the Czech Republic (grandparent breeding flocks).

- **2 HPAI outbreaks** – HPAI H5N1 confirmed on 18 November 2021 and 20 November 2021
  - a total of **4 855 breeding geese** (9 flocks)

- All geese with clinical sings were immediately culled.

- Geese without clinical sings were **repeatedly virologically tested by PCR**.

- Geese **with negative PCR test results** → selection of geese with a high genetic value to restore the breed → **813 geese selected for vaccination**.

- Culling of the other geese – positive PCR or not suitable for further breeding.
Emergency vaccination

- SVA granted the derogation from culling for geese with negative results of virological tests in accordance with Article 13(2d) of DR (EU) 2020/687.
- The vaccination plan approved by the Central Veterinary Administration.
- Vaccine: Nobilis Influenza H5N2 emulsion for injection for chickens (inactivated viral vaccine)
  - 1st dose on 16 February 2022 – 813 geese
  - 2nd dose on 18 March 2022 – 813 geese
  - 3rd dose on 5 October 2022 – 659 geese

Laboratory testing after vaccination:
- 24 March 2022 (after 2nd dose) – cloacal swabs from 120 geese, virological testing (real-time RT-PCR) → negative for AI → emergency veterinary measures in the outbreaks were lifted.
- 5 October 2022 – cloacal swabs from 80 geese, virological testing (real time RT-PCR) → negative for AI.

Conclusion:
- Using of emergency vaccination, it was possible to save the national breed „Czech goose“ with more than fifty years of tradition in the Czech Republic.
- Poultry breeders and the public perceive the possibility of vaccination very positively.
FIELD TRIALS ON HPAI VACCINATION IN DUCKS IN FRANCE
Experimental trials in mule ducks: M&M

Inventory of AI vaccines and call of interest of vaccine producers in animal health ANMV

→ Selection of 2 vaccine candidates

→ Experimental trials

1. Field trials
   Phase 1:
   3 flocks included for each of 2 vaccines (500 to 2000 birds each):
   Monitoring (PCR + serology) during the growing period to week-11
   → Vaccination practices & innocuity
   → Monitoring of seroconversion / DIVA (ELISA NP and H5)

   Phase 2:
   Same plan on a small scale (100 birds / vaccine + control)

2. Infectious challenge in BSL3 Facilities
   Challenge-tests at Week-7 and -11 of age
   → Impact of vaccination on viral excretion (Phase 1)
   → Impact of vaccination on viral transmission (R0) (Phase 2)
Experimental trials in mule ducks: Results

- **Field trials:**
  - Positive assessment of the feasibility of administration and innocuity of both vaccines
  - The combination of serology methods (NP & H5 ELISA) suitable for a DIVA strategy with serological profiles consistent for both vaccines

- **Infectious challenge trials in BSL3 facilities:**
  - **Excretion:** significant reduction in oral and cloacal viral shedding in vaccinated animals but less reduction after the challenge at 11 weeks of age compared at 7 weeks of age with similar results for both vaccines

- **Transmission:** good control of the direct transmission $R_{01}<1$ and of the airborne transmission $R_{02}$ by both vaccines

<table>
<thead>
<tr>
<th>Status</th>
<th>ELISA TITRE</th>
<th>β₁ (h⁻¹)</th>
<th>β₂ (h⁻¹)</th>
<th>Infectious period (d)</th>
<th>$R_{01}$</th>
<th>$R_{02}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non vaccinated control</td>
<td>0.45 (0.15,0.96)</td>
<td>0.15 (0.07,0.3)</td>
<td>8.1</td>
<td>88 (29.7, 186)</td>
<td>29.7 (13.5, 59.2)</td>
<td></td>
</tr>
<tr>
<td>Vaccin A</td>
<td>0.009 (5e-4, 0.042)</td>
<td>-</td>
<td>2.7 *</td>
<td>0.62 (0.05, 2.7)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Vaccin B</td>
<td>0.008 (4e-4, 0.035)</td>
<td>-</td>
<td>1.5**</td>
<td>0.28 (0.02, 1.26)</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>
HPAI vaccine-development: Hungary

Side-event to the 90th WOAH GS, Paris
21st-25th May, 2023
Vaccine development – an overview

• Field safety and efficacy test of CEVA Response AI H5 vaccine in geese
  – **Developer:** Ceva Santé Animale (Ceva-Phylaxia Veterinary Biologicals Co. Ltd.; Hungary, Budapest)
  – **Vaccine tested:** CEVA Response AI H5 (Synthetic RNA Vaccine against H5 Avian Influenza) is a synthetic RNA vaccine developed against Highly Pathogenic Avian Influenza virus subtype H5 (H5 HPAIV)
    • Vaccine for waterfowl
    • Market authorization is underway (not on the market)
Vaccine development – an overview

• Field safety and efficacy test of CEVA Response AI H5 vaccine in geese
  – Specifics of the field trial:
    • Conducted by the developer, under strict control and supervision of the Hungarian veterinary authorities;
    • Started on the 22 September, 2022;
    • Involving one goose parent stock (1204 animals: 602 vaccinated, 602 control group);
  – Results: very promising
    • Safety: mortality of vaccinated animals – 2.93% vs. mortality of control group – 76.23%
    • Efficacy: virus shedding decrease by 2log10
Italian data on vaccine efficacy tests against 2.3.4.4b clade HPAI H5N1 virus in turkeys (*Meleagris gallopavo*)

Vaccine efficacy trials in turkeys were funded by

Istituto Zooprofilattico Sperimentale delle Venezie and

The Italian Ministry of Health

ITALY

in turkeys
Italy carried out tests on fattening turkey as they are the most critical species for the introduction and the diffusion of AIVs in DPPA

**The choice of vaccination schemes was based on the:**
- Use of new generation vaccines effective against clade 2.3.4.4b
- Sustainable vaccination scheme in the field (max 2 interventions within the first month)
- Possibility of having a long-lasting immunity
- Compatibility with DIVA strategy

**The schemes tested were:**

**Heterologous vaccination**
- HVT-H5 vaccine alone on the first day of life (1d)
- HVT-H5 vaccine (1d) + sub-unit vaccine booster at 28 days (28d)
- HVT-H5 vaccine (1d) + DNA vaccine booster (28d)

**Homologous vaccination**
- Sub-unit vaccine at 8 and 28 days
- DNA vaccine at 8 and 28 days

**Infection**
Performed with a recent H5N1 HPAI strain at 40, 50 and 100 days of age
Results and next studies

Results

• HVT vaccine alone at 40 and 50 days gave suboptimal protection (therefore no tests were carried out at 100 days).
• Good clinical protection was obtained with booster (100% survival) at 50 days. The reduction in shedding was most evident with the DNA vaccine booster.
• At 100 days, vaccine protection decreased to 80% and 70% with heterologous vaccination, using respectively protein based and DNA vaccines.
• The homologous vaccination provided very unsatisfactory results (25% to 40% protection).

Tests scheduled in the forthcoming weeks

• New heterologous combinations with HVT-H5 vaccines and boosters based on new traditional (water-in-oil inactivated) and RNA vaccines.
• New challenges using an HVT-H5 vaccine expressing a hemagglutinin derived from the dominant clade H5 virus (2.3.4.4b).
• Results expected by the end of the summer.
NETHERLANDS
Vaccine trial Netherlands
in chickens from laying type
Vaccine trial Netherlands

Transmission experiment under High Containment conditions WBVR
- Four vaccines tested: 2 HVT-vaccines, 1 DNA vaccine, 1 H5N2 LPAI conventional vaccine
- 4 groups of 10 chickens; 1 control group
- Vaccination at day of hatch
- Challenge-infection of 5 birds per group with H5N1 virus; age 8 weeks
- Measuring antibodies, virus shedding and virus transmission to in-contact chickens
- Calculation of reproduction ratio

Results:
- HVT vaccines effective in preventing signs; $R=0$ [95% confidence interval 0; 0.7]
- DNA still some clinical signs; $R=1.9$ [95% confidence interval 0.6; 5.2]
- H5N2: some clinical signs, $R=1.5$ [95% confidence interval 0.3; 3.4]
Field trial Netherlands

- Vaccination of DOC in the hatchery with HVT vaccine
- Housing chickens on a ‘normal’ farm during production period
- Transmission experiments at WBVR with vaccinated birds at age
  - 8 weeks; 18 weeks; end of production:
    - Aim is
      - measuring efficacy of vaccination applied in the field
      - duration of immunity
- Start probably September 2023
- End 2025
Thank you

© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the CC BY 4.0 license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com